The NIJ also awarded Ibis a new two-year project that will fund the development and implementation of next-generation human forensics markers, which are measured on the Ibis T5000(TM) Biosensor System. In addition to the new USDA and NIJ contracts, Ibis also received new contracts from other government agencies that will fund expansion of pathogen detection and identification assays and use Ibis' assay services laboratory.
Additionally, with Lovelace Respiratory Research Institute (LRRI), Ibis has successfully completed the first year of a National Institutes of Health grant in which the Ibis influenza assay characterized over 2,000 tissue extracts to study animal models of influenza transmission. Through LRRI, Ibis has been awarded the next year of funding to continue these efforts.
"The utilization of the Ibis platform by our existing partners and the cultivation of new projects with new government agencies is a testament to the broad applicability of our technology. The enthusiasm of our government partners to invest in our technology to meet their objectives in homeland security, animal and human health, and human forensics illustrates the breadth and depth of the Ibis platform," said Steven A. Hofstadler, Ph.D., Vice President of Ibis Research.
"To date, we have earned approximately $73 million in revenue to fund development of our biosensor system and our diverse commercial assays in many different areas including biodefense and infectious disease surveillance. We are now in the position to continue to fulfill our government contracts while focusing on clinical applications with Abbott and quickly moving into larger commercial markets," concluded Mr. Treble.
ABOUT IBIS T5000 BIOSENSOR SYSTEM AND IBIS BIOSCIENCES, INC.
Ibis Biosciences, Inc., a majority-owned subsidiary of
|SOURCE Isis Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved